A formulation containing both cannabidiol (CBD) and cannabigerol (CBG) was found to be useful in combatting delayed onset muscle soreness, according to a new study published in the Journal of the International Society of Sports Nutrition.
According to the study’s researchers, cannabinoid-containing products are often “marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects.” With that in mind, this randomized, double-blind, placebo-controlled, repeated-dose pilot study “tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg).”
For the study 40 exercise-trained individuals underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24, 48, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days.
Continue reading